ClinicalTrials.gg

Program

Riluzole

Also written as “Riluzole tablet”, “Intrathecal Riluzole” and “Riluzole 50 mg orodispersible film”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Neuralgia, Postherpetic · Huntington Disease, led by 4 companies.

Furthest: phase 4, since Oct 10, 20075 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi20 open or runningphase 4since Oct 10, 2007Jan 13, 2006none ahead
Biohaven Pharmaceuticals10 open or runningphase 1since Apr 17, 2018Apr 17, 2018none ahead
Brain Trust Bio11 open or runningphase 1since May 8, 2024May 8, 2024none ahead
Cross Research10 open or runningphase 1since Mar 8, 2021Mar 8, 2021none ahead

Also a collaborator on its studies: Zambon SpA and cognitive-research-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2006First study: phase 3 study in Huntington DiseaseNew to SanofiSanofi · NCT00277602 · 537 enrolled
  2. Oct 10, 2007Phase 4 study in Amyotrophic Lateral SclerosisSanofi · NCT00542412 · 414 enrolled · Canada
  3. Apr 17, 2018Biohaven Pharmaceuticals's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to Biohaven PharmaceuticalsBiohaven Pharmaceuticals · NCT03520517 · 22 enrolled · United States
  4. Mar 8, 2021Cross Research's first study: phase 1 study in Healthy ParticipantsNew to Cross ResearchCross Research · NCT04819438 · 54 enrolled · Switzerland
  5. May 8, 2024Brain Trust Bio's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to Brain Trust BioBrain Trust Bio · NCT07093268 · 10 planned · Australia

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07093268Amyotrophic Lateral Sclerosis · Australia1Not yet recruitingBrain Trust BioJun 15, 202610
NCT04819438Healthy Participants · Switzerland1CompletedCross ResearchMar 14, 202154
NCT03520517Amyotrophic Lateral Sclerosis · United States1CompletedBiohaven PharmaceuticalsOct 8, 201822
NCT00542412Amyotrophic Lateral Sclerosis · Canada4CompletedSanofi414
NCT00277602Huntington Disease3CompletedSanofiJul 2004537

How it is read

Names in the registry

  • “Riluzole”, 2 entries
  • “Riluzole tablet”, 1 entry
  • “Intrathecal Riluzole”, 1 entry
  • “Riluzole 50 mg orodispersible film”, 1 entry
  • “BHV-0223”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.